Edesa Biotech raises CEO, President, and CFO salaries

Edesa Biotech, Inc. has approved significant increases to the annual base salaries of its three top executive officers, with the changes retroactive to July 1, 2026. The Board of Directors, acting on the recommendation of the Compensation Committee, signed off on the adjustments on October 23, 2026.

Dr. Pardeep Nijhawan, the company's Chief Executive Officer, will see his base salary rise from $357,696 to $657,423. Dr. Michael Brooks, serving as President, will have his compensation increased from $335,340 to $591,681. Peter Weiler, the Chief Financial Officer, will move from a base salary of $300,000 to $525,938. These increases are being implemented pursuant to the respective employment agreements held by each officer.

The filing notes that the base salaries of Edesa's executive officers had not been adjusted since 2023. The new compensation structure is part of a broader compensatory arrangement disclosed in the company's Form 8-K current report filed with the U.S. Securities and Exchange Commission.

For Dr. Nijhawan specifically, the arrangement includes a unique payment structure for a portion of his cash salary. As previously disclosed, 90% of his monthly base salary otherwise payable in cash will continue to be issued as fully vested restricted share units. These units are granted under the company's 2019 Equity Incentive Compensation Plan.

The details provided in the 8-K regarding these compensatory arrangements are not complete and are qualified by reference to the full employment agreements. Those agreements were filed as exhibits to Edesa's Annual Report on Form 10-K for the year ended September 30, 2025, which was submitted to the SEC on December 12, 2025.

Edesa Biotech is incorporated in British Columbia, Canada, and maintains its principal executive offices at 333 Bay Street, Suite 2400, in Toronto, Ontario. The company's common shares trade on The Nasdaq Stock Market LLC under the ticker symbol EDSA. The report was signed by Peter J. Weiler in his capacity as Chief Financial Officer.